Amylyx Pharmaceuticals Announces Exclusive AMX0035 Distribution Agreement with Israel-Based NeopharmBusiness Wire • 01/17/23
100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make MiraclesInvestors Business Daily • 12/30/22
Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx ConferenceBusiness Wire • 11/22/22
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The HelmInvestors Business Daily • 11/16/22
Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022Business Wire • 11/03/22
NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks VideoPRNewsWire • 10/18/22
Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness Wire • 10/11/22
Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockBusiness Wire • 10/07/22
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALSBusiness Wire • 09/29/22
IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long BattleInvestors Business Daily • 09/29/22
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and DiscoveriesBusiness Wire • 09/14/22